Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fine-mapping genomic loci refines bipolar disorder risk genes

  • Koromina, Maria|||0000-0001-8843-082X
  • Ravi, Ashvin
  • Panagiotaropoulou, Georgia
  • Schilder, Brian M.|||0000-0001-5949-2191
  • Humphrey, Jack
  • Braun, Alice|||0000-0003-1145-0261
  • Bigdeli, Tim B.|||0000-0003-2215-5946
  • Chatzinakos, Chris
  • Coombes, Brandon J.|||0000-0003-4322-5923
  • Kim, Jaeyoung|||0000-0001-6983-7907
  • Liu, Xiaoxi|||0000-0002-1933-8613
  • Terao, Chikashi|||0000-0002-6452-4095
  • O'Connell, Kevin S.|||0000-0002-6865-8795
  • Adams, Mark J
  • Adolfsson, Rolf
  • Alda, Martin|||0000-0001-9544-3944
  • Alfredsson, Lars|||0000-0003-1688-6697
  • Andlauer, Till F. M.|||0000-0002-2917-5889
  • Andreassen, Ole A.|||0000-0002-4461-3568
  • Antoniou, Anastasia
  • Baune, Bernhard T.|||0000-0001-6548-426X
  • Bengesser, Susanne
  • Biernacka, Joanna
  • Boehnke, Michael|||0000-0002-6442-7754
  • Bosch, Rosa|||0000-0002-7596-183X
  • Cairns, Murray J.
  • Carr, Vaughan J.
  • Casas Brugué, Miquel|||0000-0003-3496-8522
  • Catts, Stanley
  • Cichon, Sven|||0000-0002-9475-086X
  • Corvin, Aiden
  • Craddock, Nicholas
  • Dafnas, Konstantinos
  • Dalkner, Nina
  • Dannlowski, Udo|||0000-0002-0623-3759
  • Degenhardt, Franziska
  • Di Florio, Arianna
  • Dikeos, Dimitris
  • Fellendorf, Frederike Tabea
  • Ferentinos, Panagiotis|||0000-0001-8531-5623
  • Forstner, Andreas J.
  • Forty, Liz|||0000-0002-4349-8414
  • Frye, Mark
  • Fullerton, Janice M.|||0000-0003-4014-4490
  • Gawlik, Micha
  • Gizer, Ian R.
  • Gordon-Smith, Katherine
  • Green, Melissa J.
  • Grigoroiu-Serbanescu, Maria
  • Guzman-Parra, Jose|||0000-0002-1463-6435
  • Hahn, Tim|||0000-0002-8929-4134
  • Henskens, Frans
  • Hillert, Jan|||0000-0002-7386-6732
  • Jablensky, Assen V.
  • Jones, Lisa|||0000-0002-5122-8334
  • Jones, Ian
  • Jonsson, Lina
  • Kelsoe, John R.
  • Kircher, Tilo|||0000-0002-2514-2625
  • Kirov, George|||0000-0002-3427-3950
  • Kittel-Schneider, Sarah|||0000-0003-3057-6150
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Landén, Mikael|||0000-0002-4496-6451
  • Leboyer, Marion|||0000-0001-5473-3697
  • Lenger, Melanie
  • Lissowska, Jolanta
  • Lochner, Christine|||0000-0002-4766-3704
  • Loughland, Carmel
  • MacIntyre, Donald J.|||0000-0001-6963-1335
  • Martin, Nicholas G.|||0000-0003-4069-8020
  • Maratou, Eirini
  • Mathews, Carol A.|||0000-0003-2208-7058
  • Mayoral-Cleries, Fermín
  • McElroy, Susan L.
  • McGregor, Nathaniel|||0000-0001-7195-4993
  • McIntosh, Andrew M.|||0000-0002-0198-4588
  • McQuillin, Andrew|||0000-0003-1567-2240
  • Michie, Patricia|||0000-0002-4169-8519
  • Mitchell, Philip B.
  • Moutsatsou, Paraskevi
  • Mowry, Bryan J.|||0000-0002-4115-5645
  • Müller-Myhsok, Bertram
  • Myers, Richard M.
  • Nenadić, Igor|||0000-0002-0749-7473
  • Nievergelt, Caroline M.
  • Nöthen, Markus M.|||0000-0002-8770-2464
  • Nurnberger, John
  • O'Donovan, Michael C.|||0000-0001-7073-2379
  • 'Donovan, Claire O.
  • Ophoff, Roel A.
  • Owen, Michael J.
  • Pantelis, Christos|||0000-0002-9565-0238
  • Pato, Carlos|||0000-0002-5858-266X
  • Pato, Michele T.
  • Patrinos, George P.
  • Pawlak, Joanna M.
  • Perlis, Roy H.|||0000-0002-5862-6757
  • Porichi, Evgenia
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Ramos-Quiroga, Josep Antoni|||0000-0003-1622-0350
  • Reif, Andreas|||0000-0002-0992-634X
  • Reininghaus, Eva Z.
  • Ribasés Haro, Marta|||0000-0003-1039-1116
  • Rietschel, Marcella|||0000-0002-5236-6149
  • Schall, Ulrich
  • Schofield, Peter R.|||0000-0003-2967-9662
  • Schulze, Thomas G.
  • Scott, Laura J.|||0000-0002-4886-5084
  • Scott, Rodney J.|||0000-0001-7724-3404
  • Serretti, Alessandro
  • Smoller, Jordan W.|||0000-0002-0381-6334
  • Świątkowska, Beata
  • Soler Artigas, María|||0000-0002-3213-1107
  • Stein, Dan J.|||0000-0001-7218-7810
  • Streit, Fabian|||0000-0003-1080-4339
  • Toma, Claudio|||0000-0003-3901-7507
  • Tooney, Paul
  • Vawter, Marquis P.
  • Vieta, Eduard|||0000-0002-0548-0053
  • Vincent, John B.
  • Waldman, Irwin D.|||0000-0002-6862-1837
  • Weickert, Cynthia Shannon
  • Weickert, Thomas
  • Witt, Stephanie H.|||0000-0002-1571-1468
  • Hong, Kyung Sue
  • Ikeda, Masashi|||0000-0001-6237-2449
  • Iwata, Nakao|||0000-0003-3189-6076
  • Won, Hong Hee
  • Edenberg, Howard J.|||0000-0003-0344-9690
  • Ripke, Stephan|||0000-0003-3622-835X
  • Raj, Towfique|||0000-0002-9355-5704
  • Coleman, Jonathan R.I.
  • Mullins, Niamh
Bipolar disorder is a heritable mental illness with complex etiology. While the largest published genome-wide association study identified 64 bipolar disorder risk loci, the causal SNPs and genes within these loci remain unknown. We applied a suite of statistical and functional fine-mapping methods to these loci and prioritized 17 likely causal SNPs for bipolar disorder. We mapped these SNPs to genes and investigated their likely functional consequences by integrating variant annotations, brain cell-type epigenomic annotations, brain quantitative trait loci and results from rare variant exome sequencing in bipolar disorder. Convergent lines of evidence supported the roles of genes involved in neurotransmission and neurodevelopment, including SCN2A, TRANK1, DCLK3, INSYN2B, SYNE1, THSD7A, CACNA1B, TUBBP5, FKBP2, RASGRP1, FURIN, FES, MED24 and THRA among others in bipolar disorder. These represent promising candidates for functional experiments to understand biological mechanisms and therapeutic potential. Additionally, we demonstrated that fine-mapping effect sizes can improve performance of bipolar disorder polygenic risk scores across diverse populations and present a high-throughput fine-mapping pipeline.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

An evidence map of actigraphy studies exploring longitudinal associations between rest-activity rhythms and course and outcome of bipolar disorders

  • Scott, Jan
  • Colom, Francesc
  • Young, Allan
  • Bellivier, Frank
  • Etain, Bruno
Background: Evidence mapping is a structured approach used to synthesize the state-of-the-art in an emerging field of research when systematic reviews or meta-analyses are deemed inappropriate. We employed this strategy to summarise knowledge regarding longitudinal ecological monitoring of rest-activity rhythms (RAR) and disease modifiers, course of illness, treatment response or outcome in bipolar disorders (BD). Structure: We had two key aims: (1) to determine the number and type of actigraphy studies of in BD that explored data regarding: outcome over time (e.g. relapse/recurrence according to polarity, or recovery/remission), treatment response or illness trajectories and (2) to examine the range of actigraphy metrics that can be used to estimate disruptions of RAR and describe which individual circadian rhythm or sleep-wake cycle parameters are most consistently associated with outcome over time in BD. The mapping process incorporated four steps: clarifying the project focus, describing boundaries and 'coordinates' for mapping, searching the literature and producing a brief synopsis with summary charts of the key outputs. Twenty-seven independent studies (reported in 29 publications) were eligible for inclusion in the map. Most were small-scale, with the median sample size being 15 per study and median duration of actigraphy being about 7 days (range 1-210). Interestingly, 17 studies comprised wholly or partly of inpatients (63%). The available evidence indicated that a discrete number of RAR metrics are more consistently associated with transition between different phases of BD and/or may be predictive of longitudinal course of illness or treatment response. The metrics that show the most frequent associations represent markers of the amount, timing, or variability of RAR rather than the sleep quality metrics that are frequently targeted in contemporary studies of BD. Conclusions: Despite 50 years of research, use of actigraphy to assess RAR in longitudinal studies and examination of these metrics and treatment response, course and outcome of BD is under-investigated. This is in marked contrast to the extensive literature on case-control or cross-sectional studies of actigraphy, especially typical sleep analysis metrics in BD. However, given the encouraging findings on putative RAR markers, we recommend increased study of putative circadian phenotypes of BD., FB is the Principal Investigator and all the authors are investigators on the R-LiNK (Response to Lithium Network) project. This project has received funding from the European Union Horizon 2020 research and innovation program ((EU.3.1.1. Understanding health, wellbeing and disease: Grant No 754907). BE received funding from: Institut National de la Santé et de la Recherche Médicale (INSERM – Research Protocol C0829), Assistance Publique des Hôpitaux de Paris (APHP – Research Protocol GAN12). FC received funding from: Spanish Ministry of Economy and Competitiveness, through a FIS (PI15/00588; PI19/00009), and the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya, Government of Catalonia (2017_SGR_134). AY received funding from: National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Safety intervention for improving functioning in suicidal attempters (STRONG): A secondary prevention study. Study rationale and research protocol

  • Roberto, Natalia
  • Toll, Alba
  • Elices, Matilde
  • Pérez Solà, Víctor
  • Grande, Iria
Data de publicació electrònica: 07-09-2023, Background: Suicide is one of the most largely preventable causes of death worldwide. The aim of the STRONG study is to assess the effectiveness of a specific intervention (an extended Safety Planning Intervention) called iFightDepression-SURVIVE (iFD-S) in suicidal attempters by changes in psychosocial functioning. As secondary outcomes, quality of life, cognitive performance, clinical state and neuroimaging correlates will be considered. Objective: To describe the rationale and design of the STRONG study, an extension of the SURVIVE study, a national multicenter cohort about on prevention in suicidal attempters. Methods: The STRONG study is a two-year clinical trial. A total sample of 60 patients will be randomly allocated to two arms: a group will receive a iFD-S and treatment as usual (TAU) (n=30 treatment group), while another group will exclusively receive TAU (n=30 control group). There will be three study points: baseline; 3-month; and 6-month follow-up assessments, all of which will include rater-blinded evaluation of psychosocial functioning, quality of life, clinical state, cognitive performance and neuroimaging acquisition. Results: It is expected to obtain data on the efficacy of iFD-S in patients who have committed a suicide attempt. Conclusion: Results will provide insight into the effectiveness of IFD-S in suicidal attempters with respect to improvements in psychosocial functioning, quality of life, cognition, and neuroimaging correlates. Clinical trials id: NCT05655390., EV wishes to acknowledge the support from CIBER – Consorcio Centro de Investigación Biomédica en Red – (CB07/09/0004), Instituto de Salud Carlos III, the Spanish Ministry of Science and Innovation (PI18/00805, PI21/00787), Instituto de Salud Carlos III – Fondo Europeo de Desarrollo Regional (FEDER). Unión Europea. “Una manera de hacer Europa”, cofinanciado por la Unión Europea; the CERCA Program/Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement (2021 SGR 01358). Departament de Salut de la Generalitat de Catalunya, Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020 (SLT006/17/00357). Thanks are also given for the support received from the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing and disease: grant no. 754907 and EU.3.1.3. Treating and managing disease: grant no. 945151). ME has a Juan de la Cierva research contract awarded by the ISCIII (FJCI-2017-31738). VP, ME, and AT want to thank unrestricted research funding from “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement” (2017 SGR 134 to “Mental Health Research Group”), Generalitat de Catalunya (Government of Catalonia). PAS has received partial support from the Government of the Principality of Asturias PCTI-2021-2023 IDI/2021/111, the Fundación para la Investigación e Innovación Biosanitaria del Principado de Asturias (FINBA), and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, and Ministerio de Ciencia e Innovación. The funders had no role in the study design, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK Initiative

  • Scott, Jan
  • García-Estela, Aitana
  • Bellivier, Frank
Background: Lithium is recommended as a first line treatment for bipolar disorders. However, only 30% of patients show an optimal outcome and variability in lithium response and tolerability is poorly understood. It remains difficult for clinicians to reliably predict which patients will benefit without recourse to a lengthy treatment trial. Greater precision in the early identification of individuals who are likely to respond to lithium is a significant unmet clinical need. Structure: The H2020-funded Response to Lithium Network (R-LiNK; http://www.r-link.eu.com/ ) will undertake a prospective cohort study of over 300 individuals with bipolar-I-disorder who have agreed to commence a trial of lithium treatment following a recommendation by their treating clinician. The study aims to examine the early prediction of lithium response, non-response and tolerability by combining systematic clinical syndrome subtyping with examination of multi-modal biomarkers (or biosignatures), including omics, neuroimaging, and actigraphy, etc. Individuals will be followed up for 24 months and an independent panel will assess and classify each participants' response to lithium according to predefined criteria that consider evidence of relapse, recurrence, remission, changes in illness activity or treatment failure (e.g. stopping lithium; new prescriptions of other mood stabilizers) and exposure to lithium. Novel elements of this study include the recruitment of a large, multinational, clinically representative sample specifically for the purpose of studying candidate biomarkers and biosignatures; the application of lithium-7 magnetic resonance imaging to explore the distribution of lithium in the brain; development of a digital phenotype (using actigraphy and ecological momentary assessment) to monitor daily variability in symptoms; and economic modelling of the cost-effectiveness of introducing biomarker tests for the customisation of lithium treatment into clinical practice. Also, study participants with sub-optimal medication adherence will be offered brief interventions (which can be delivered via a clinician or smartphone app) to enhance treatment engagement and to minimize confounding of lithium non-response with non-adherence. Conclusions: The paper outlines the rationale, design and methodology of the first study being undertaken by the newly established R-LiNK collaboration and describes how the project may help to refine the clinical response phenotype and could translate into the personalization of lithium treatment., This project has received funding from the European Union Horizon 2020 research and innovation program ((EU.3.1.1. Understanding health, wellbeing and disease: Grant No 754907).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

An evidence map of actigraphy studies exploring longitudinal associations between rest-activity rhythms and course and outcome of bipolar disorders

  • Scott, Jan
  • Colom, Francesc
  • Young, Allan
  • Bellivier, Frank
  • Etain, Bruno
Background: Evidence mapping is a structured approach used to synthesize the state-of-the-art in an emerging field of research when systematic reviews or meta-analyses are deemed inappropriate. We employed this strategy to summarise knowledge regarding longitudinal ecological monitoring of rest-activity rhythms (RAR) and disease modifiers, course of illness, treatment response or outcome in bipolar disorders (BD). Structure: We had two key aims: (1) to determine the number and type of actigraphy studies of in BD that explored data regarding: outcome over time (e.g. relapse/recurrence according to polarity, or recovery/remission), treatment response or illness trajectories and (2) to examine the range of actigraphy metrics that can be used to estimate disruptions of RAR and describe which individual circadian rhythm or sleep-wake cycle parameters are most consistently associated with outcome over time in BD. The mapping process incorporated four steps: clarifying the project focus, describing boundaries and 'coordinates' for mapping, searching the literature and producing a brief synopsis with summary charts of the key outputs. Twenty-seven independent studies (reported in 29 publications) were eligible for inclusion in the map. Most were small-scale, with the median sample size being 15 per study and median duration of actigraphy being about 7 days (range 1-210). Interestingly, 17 studies comprised wholly or partly of inpatients (63%). The available evidence indicated that a discrete number of RAR metrics are more consistently associated with transition between different phases of BD and/or may be predictive of longitudinal course of illness or treatment response. The metrics that show the most frequent associations represent markers of the amount, timing, or variability of RAR rather than the sleep quality metrics that are frequently targeted in contemporary studies of BD. Conclusions: Despite 50 years of research, use of actigraphy to assess RAR in longitudinal studies and examination of these metrics and treatment response, course and outcome of BD is under-investigated. This is in marked contrast to the extensive literature on case-control or cross-sectional studies of actigraphy, especially typical sleep analysis metrics in BD. However, given the encouraging findings on putative RAR markers, we recommend increased study of putative circadian phenotypes of BD., FB is the Principal Investigator and all the authors are investigators on the R-LiNK (Response to Lithium Network) project. This project has received funding from the European Union Horizon 2020 research and innovation program ((EU.3.1.1. Understanding health, wellbeing and disease: Grant No 754907). BE received funding from: Institut National de la Santé et de la Recherche Médicale (INSERM – Research Protocol C0829), Assistance Publique des Hôpitaux de Paris (APHP – Research Protocol GAN12). FC received funding from: Spanish Ministry of Economy and Competitiveness, through a FIS (PI15/00588; PI19/00009), and the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya, Government of Catalonia (2017_SGR_134). AY received funding from: National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK Initiative

  • Scott, Jan
  • García-Estela, Aitana
  • Bellivier, Frank
Background: Lithium is recommended as a first line treatment for bipolar disorders. However, only 30% of patients show an optimal outcome and variability in lithium response and tolerability is poorly understood. It remains difficult for clinicians to reliably predict which patients will benefit without recourse to a lengthy treatment trial. Greater precision in the early identification of individuals who are likely to respond to lithium is a significant unmet clinical need. Structure: The H2020-funded Response to Lithium Network (R-LiNK; http://www.r-link.eu.com/ ) will undertake a prospective cohort study of over 300 individuals with bipolar-I-disorder who have agreed to commence a trial of lithium treatment following a recommendation by their treating clinician. The study aims to examine the early prediction of lithium response, non-response and tolerability by combining systematic clinical syndrome subtyping with examination of multi-modal biomarkers (or biosignatures), including omics, neuroimaging, and actigraphy, etc. Individuals will be followed up for 24 months and an independent panel will assess and classify each participants' response to lithium according to predefined criteria that consider evidence of relapse, recurrence, remission, changes in illness activity or treatment failure (e.g. stopping lithium; new prescriptions of other mood stabilizers) and exposure to lithium. Novel elements of this study include the recruitment of a large, multinational, clinically representative sample specifically for the purpose of studying candidate biomarkers and biosignatures; the application of lithium-7 magnetic resonance imaging to explore the distribution of lithium in the brain; development of a digital phenotype (using actigraphy and ecological momentary assessment) to monitor daily variability in symptoms; and economic modelling of the cost-effectiveness of introducing biomarker tests for the customisation of lithium treatment into clinical practice. Also, study participants with sub-optimal medication adherence will be offered brief interventions (which can be delivered via a clinician or smartphone app) to enhance treatment engagement and to minimize confounding of lithium non-response with non-adherence. Conclusions: The paper outlines the rationale, design and methodology of the first study being undertaken by the newly established R-LiNK collaboration and describes how the project may help to refine the clinical response phenotype and could translate into the personalization of lithium treatment., This project has received funding from the European Union Horizon 2020 research and innovation program ((EU.3.1.1. Understanding health, wellbeing and disease: Grant No 754907).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Safety intervention for improving functioning in suicidal attempters (STRONG): A secondary prevention study. Study rationale and research protocol

  • Roberto, Natalia
  • Toll Privat, Alba
  • Elices, Matilde
  • Pérez Solá, Victor
  • Grande, Iria
Data de publicació electrònica: 07-09-2023, Background: Suicide is one of the most largely preventable causes of death worldwide. The aim of the STRONG study is to assess the effectiveness of a specific intervention (an extended Safety Planning Intervention) called iFightDepression-SURVIVE (iFD-S) in suicidal attempters by changes in psychosocial functioning. As secondary outcomes, quality of life, cognitive performance, clinical state and neuroimaging correlates will be considered. Objective: To describe the rationale and design of the STRONG study, an extension of the SURVIVE study, a national multicenter cohort about on prevention in suicidal attempters. Methods: The STRONG study is a two-year clinical trial. A total sample of 60 patients will be randomly allocated to two arms: a group will receive a iFD-S and treatment as usual (TAU) (n=30 treatment group), while another group will exclusively receive TAU (n=30 control group). There will be three study points: baseline; 3-month; and 6-month follow-up assessments, all of which will include rater-blinded evaluation of psychosocial functioning, quality of life, clinical state, cognitive performance and neuroimaging acquisition. Results: It is expected to obtain data on the efficacy of iFD-S in patients who have committed a suicide attempt. Conclusion: Results will provide insight into the effectiveness of IFD-S in suicidal attempters with respect to improvements in psychosocial functioning, quality of life, cognition, and neuroimaging correlates. Clinical trials id: NCT05655390., EV wishes to acknowledge the support from CIBER – Consorcio Centro de Investigación Biomédica en Red – (CB07/09/0004), Instituto de Salud Carlos III, the Spanish Ministry of Science and Innovation (PI18/00805, PI21/00787), Instituto de Salud Carlos III – Fondo Europeo de Desarrollo Regional (FEDER). Unión Europea. “Una manera de hacer Europa”, cofinanciado por la Unión Europea; the CERCA Program/Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia I Coneixement (2021 SGR 01358). Departament de Salut de la Generalitat de Catalunya, Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020 (SLT006/17/00357). Thanks are also given for the support received from the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing and disease: grant no. 754907 and EU.3.1.3. Treating and managing disease: grant no. 945151). ME has a Juan de la Cierva research contract awarded by the ISCIII (FJCI-2017-31738). VP, ME, and AT want to thank unrestricted research funding from “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement” (2017 SGR 134 to “Mental Health Research Group”), Generalitat de Catalunya (Government of Catalonia). PAS has received partial support from the Government of the Principality of Asturias PCTI-2021-2023 IDI/2021/111, the Fundación para la Investigación e Innovación Biosanitaria del Principado de Asturias (FINBA), and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, and Ministerio de Ciencia e Innovación. The funders had no role in the study design, decision to publish, or preparation of the manuscript.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

An evidence map of actigraphy studies exploring longitudinal associations between rest-activity rhythms and course and outcome of bipolar disorders

  • Scott, Jan
  • Colom, Francesc|||0000-0002-9516-9030
  • Young, Allan|||0000-0003-2291-6952
  • Bellivier, Frank
  • Etain, Bruno|||0000-0002-5377-1488
Evidence mapping is a structured approach used to synthesize the state-of-the-art in an emerging field of research when systematic reviews or meta-analyses are deemed inappropriate. We employed this strategy to summarise knowledge regarding longitudinal ecological monitoring of rest-activity rhythms (RAR) and disease modifiers, course of illness, treatment response or outcome in bipolar disorders (BD). We had two key aims: (1) to determine the number and type of actigraphy studies of in BD that explored data regarding: outcome over time (e.g. relapse/recurrence according to polarity, or recovery/remission), treatment response or illness trajectories and (2) to examine the range of actigraphy metrics that can be used to estimate disruptions of RAR and describe which individual circadian rhythm or sleep-wake cycle parameters are most consistently associated with outcome over time in BD. The mapping process incorporated four steps: clarifying the project focus, describing boundaries and 'coordinates' for mapping, searching the literature and producing a brief synopsis with summary charts of the key outputs. Twenty-seven independent studies (reported in 29 publications) were eligible for inclusion in the map. Most were small-scale, with the median sample size being 15 per study and median duration of actigraphy being about 7 days (range 1-210). Interestingly, 17 studies comprised wholly or partly of inpatients (63%). The available evidence indicated that a discrete number of RAR metrics are more consistently associated with transition between different phases of BD and/or may be predictive of longitudinal course of illness or treatment response. The metrics that show the most frequent associations represent markers of the amount, timing, or variability of RAR rather than the sleep quality metrics that are frequently targeted in contemporary studies of BD. Despite 50 years of research, use of actigraphy to assess RAR in longitudinal studies and examination of these metrics and treatment response, course and outcome of BD is under-investigated. This is in marked contrast to the extensive literature on case-control or cross-sectional studies of actigraphy, especially typical sleep analysis metrics in BD. However, given the encouraging findings on putative RAR markers, we recommend increased study of putative circadian phenotypes of BD.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Lithium response in bipolar disorder: epigenome-wide dna methylation signatures and epigenetic aging

  • Zafrilla López, M.
  • Acosta Díez, M.
  • Mitjans, M.
  • Saiz Martínez, Pilar Alejandra
  • García-Portilla González, María Paz|||0000-0003-3643-1622
  • González Blanco, Leticia|||0000-0001-6238-4773
  • Bobes, Julio|||0000-0003-2187-4033
This work was supported by the Institute of Health Carlos III through projects PI16/00998, PI17/01122, PI18/00805, PI21/00787, PI22/01048 and PI22/00431 co-funded by European Regional Development Fund (ERDF)/European Social Fund “Investing in your future”, (...) the Spanish ‘Ministerio de Ciencia, Innovaci´ on y Universidades’ (PID2021–1277760B-I00, PID2022–139740OA-I00) (...) MM, SP, BA, AB, AGP, EJ, AB, PAS, PGP, LGB and JB, thanks the support by CIBER -Consorcio Centro de Investigación Biomédica en Red, Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (CB07/09/0037, CB07/09/0004 and CB07/09/0020). MM was supported by Horizon 2020 Marie Sklodowska-Curie Individual Fellowship from the European Commission under grant agreement no. 841899 (GRASAD). This article is part of the grant RYC2021–033573-I funded by MICIU/AEI/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR. AGP receives financial support from an educational grant from the Spanish Ministry of Health, Instituto de Salud Carlos III (CM21/00094) and by the European Social Fund Plus (FSE+). EV (...) support of the European Union Horizon 2020 research and innovation program (EU.3.1.1. Understanding health, wellbeing, and disease: Grant No 754907 and EU.3.1.3. Treating and managing disease: Grant No 945151)., Zafrilla-López M., Acosta-Díez M., Mitjans M., Giménez-Palomo A., Saiz P.A., Barrot-Feixat C., Jiménez E., Papiol S., Ruiz V., Gavín P., García-Portilla M.P., González-Blanco L., Bobes J., Schulze T.G., Vieta E., Benabarre A., Arias B.